Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Mechanicsville, Virginia Clinical Trials

A listing of Mechanicsville, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (18) clinical trials

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

7.87 miles

Learn More »

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

PRIMARY OBJECTIVES: I. Establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of recombinant human interleukin (rhIL)-12 in combination with MK-3475 (pembrolizumab). SECONDARY OBJECTIVES: I. Evaluate the safety of the regimen by continuously monitoring adverse events that will be documented utilizing Common Terminology Criteria for Adverse ...

Phase

7.87 miles

Learn More »

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

This is a 16-week randomized, double blind, placebo-controlled trial designed to determine the effectiveness of zonisamide treatment for reducing heavy drinking and overall drinking in 160 treatment-seeking, regularly heavy drinking, alcohol-dependent civilians who want to quit drinking or reduce consumption to non-hazardous levels. The investigators will use state-of-the-art methodology and ...

Phase

7.87 miles

Learn More »

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

To determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy. RP2Ds and schedule of sorafenib and vorinostat defined as the doses and schedule that are the same as or less ...

Phase

7.87 miles

Learn More »

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

Phase

7.87 miles

Learn More »

A Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy Non-physically Dependent Recreational Opioid Users.

This study is a single-center study in which approximately 24 subjects will be randomized to one of two treatment groups. Subjects will enter a screening period between Day -28 and Day -2. Upon meeting all criteria for enrollment, on Day -1 subjects will enter the clinical research study unit (CRSU) ...

Phase

7.87 miles

Learn More »

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

This is a Phase 1, open-label, single ascending dose study of MT-3921 in subjects with spinal cord injury.

Phase

7.87 miles

Learn More »

A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a Phase I, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), RO7082859, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following the pre-treatment with a one-time, fixed dose of obinutuzumab. ...

Phase

8.88 miles

Learn More »